Work

Gotistobart in combination with pembrolizumab in patients with advanced melanoma who have progressed on PD-1 inhibitors with or without CTLA-4 inhibitors.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.9551

Authors: Siwen Hu-Lieskovan, Kari Lynn Kendra, Kai He, Bently Patrick Doonan, Eric S. Schaefer, Edward Arrowsmith, Ki Young Chung, Eric D. Whitman, Ulka N. Vaishampayan, Svetlana Shpyro, Qiong Wang, Juanjuan Su, Chris Leung, Kazuharu Kai, Yang Liu, Pan Zheng, Tianhong Li

Institutions: University of Utah, The Ohio State University, University of Florida Health, University of Florida, Highlands Oncology Group, Tennessee Oncology, Prisma Health, Atlantic Health System, University of Michigan, BioNTech (Germany), UC Davis Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Small Business Innovation Research

Award: G3196658760

OpenAlex ID: W4410818811

Cites:

Cited by:

Related to: 10